DataMeds AI, Inc. MEDS
in 2022, we are a holding company for existing and future planned operating companies centered around pharmaceuticals and healthcare
services. We seek to be a micro health ecosystem, with a portfolio of companies consisting of a pharmacy, wholesale operations, and a
technology division that provides a novel platform for hub and clinical services. We are focused on improving the lives of patients while
delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. With the successful integration of its
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $23.3M | $18.1M | — | — |
| Cost of revenue | $29.8M | $16.4M | — | — |
| Gross profit | -$6.4M | $1.8M | — | — |
| SG&A | $70.3M | $6.8M | $2.9M | — |
| Total operating expenses | $87.3M | $7.9M | $2.9M | — |
| Operating income | -$93.7M | -$6.1M | -$2.9M | — |
| Interest expense | $4.6M | $831.5K | $15.1K | — |
| Pre-tax income | -$101.3M | -$6.9M | -$2.9M | — |
| Net income | -$101.3M | -$6.9M | -$2.9M | — |
| EPS, basic | -1.43 | -0.15 | -0.06 | — |
| EPS, diluted | -1.43 | -0.15 | -0.06 | — |
| Shares, diluted (wtd. avg.) | 71.0M | 47.3M | 44.7M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $42.6K | $1.0M | $1.4K | — |
| Inventory | $1.6M | $9.5M | — | — |
| Total current assets | $2.8M | $15.2M | $338.4K | — |
| Property, plant and equipment | $229.4K | $388.2K | — | — |
| Goodwill | $14.2M | $16.2M | — | — |
| Other intangibles | $2.5M | $1.6M | — | — |
| Total assets | $30.5M | $57.3M | $338.4K | — |
| Short-term debt | $10.9M | $11.9M | $350.0K | — |
| Total current liabilities | $29.8M | $38.0M | $2.9M | — |
| Long-term debt | $12.6M | $11.5M | — | — |
| Total liabilities | $42.9M | $50.6M | $3.2M | — |
| Retained earnings | -$111.0M | -$9.8M | -$2.9M | — |
| Total equity | -$12.4M | $6.7M | -$2.9M | -$5.2K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$10.9M | -$1.2M | -$349.1K | — |
| Depreciation and amortisation | $158.8K | $67.6K | — | — |
| Stock-based compensation | $200.0K | $1.1M | — | — |
| Investing cash flow | -$881.5K | $469.1K | — | — |
| Financing cash flow | $10.8M | $1.8M | $350.5K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-018958.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | $18.1M | $23.3M |
| Gross profit | — | — | $1.8M | -$6.4M |
| Net income | — | -$2.9M | -$6.9M | -$101.3M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event Item 8.01
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Other event Item 8.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Other event Item 8.01
- Material agreement signed Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 5122
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MCK | MCKESSON CORP | $116.68B | 26.1x | 12.4% |
| COR | Cencora, Inc. | $63.16B | 41.6x | 9.3% |
| CAH | CARDINAL HEALTH INC | $58.04B | 34.5x | 14.2% |
| HLF | HERBALIFE LTD. | $1.40B | 6.1x | 0.9% |
| NUS | NU SKIN ENTERPRISES, INC. | $233.2M | 1.5x | -14.3% |
| COSM | Cosmos Health Inc. | $26.3M | — | 19.9% |
| HWH | HWH International Inc. | $20.7M | — | -30.8% |
| HKPD | Cellyan Biotechnology Co., Ltd | — | — | — |